Meanwhile, the BSE Sensex was up 53.25 points, or 0.31% to 17,221.21.
On BSE, 13,861 shares were traded in the counter as against an average daily volume of 17,649 shares in the past one quarter.
The stock hit a high of Rs 1705 so far during the day, which is a record high for the counter. The stock hit a low of Rs 1681.15 so far during the day. The stock had hit a 52-week low of Rs 979.20 on 12 March 2009.
The large-cap stock had outperformed the market over the past one month till 11 March 2010, gaining 10.95% as compared to the Sensex's 6.29% rise. It had also outperformed the market in the past one quarter, rising 17.01% as compared to the Sensex's return of 0.29%.
The company's equity capital is Rs 103.56 crore. Face value per share is Rs 5.
The current price of Rs 1700.50 discounts the company's Q3 December 2009 annualized EPS of Rs 61.42, by a PE multiple of 27.69.
Oxaliplatin injection is the generic version of Sanofi-Aventis' Eloxatin injection. The drug used for treating colon and rectal cancer.
Sun Pharmaceuticals Industries' net profit rose 23.9% to Rs 318.04 crore on a 22.4% fall in sales to Rs 489.64 crore in Q3 December 2009 over Q3 December 2008.
Sun Pharma is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several markets across the world.
As on January 2010, promoters have pledged 6.85 lakh shares representing 0.33% of the equity capital of the company. The total promoters shareholding in the company is 63.71% (end December 2009).